Medicine has two things to offer when viral pandemics hit: vaccines and therapeutics. While it is hard to undervalue the noble goal of rapidly developing and rolling out safe vaccines that effectively reduce disease severity, and potentially even rates of infection, some would argue that therapeutic options for COVID-19 have been underappreciated. While it is tough to find good estimates of how much funding has been made available for each strategy, it is probably fair to say that approving new drugs for COVID-19 has never been compared to the moon shot.